Abhishek Kumar Pandey¹, Priyanka Bang², Sonam Pandey³, Nikita Dwivedi⁴ and Avishkar Singh Parmar⁵*

¹Senior Resident, Department of Dentistry, Kalyan Singh Super Speciality Cancer Institute, Lucknow, (U.P)., India
²Department of Prosthodontics, Crown and Bridge, Sardar Patel Postgraduate Institute of Dental and Medical Sciences, Lucknow, (U.P)., India
³JR-II, Department of Periodontology and Implantology, BBD College of Dental Sciences, Lucknow, (U.P)., India
⁴BDS, Sardar Patel Postgraduate Institute of Dental and Medical Sciences, Lucknow, (U.P)., India
⁵Junior Resident, Department of Dentistry, Kalyan Singh Super Speciality Cancer Institute, Lucknow, (U.P)., India

*Corresponding Author: Abhishek Kumar Pandey, Senior Resident, Department of Dentistry, Kalyan Singh Super Speciality Cancer Institute, Lucknow, (U.P)., India. Social Account Links/ID:-

Cureus ID: abhishekpandeykv@rediffmail.com
Link https://www.cureus.com/users/994512-dr-abhishek-kumar-pandey
Orcid : 0009-0004-1932-3915
Orcid ID Link : https://orcid.org/0009-0004-1932-3915
PubMed ID : abhishek2026@orcid

Received: August 05, 2026; Published: August 27, 2026

Head and Neck cancers account for a significant proportion of cancer cases worldwide and are associated with considerably morbidity. The oral cavity is often the primary site affected by the disease as well as by its treatment. Dentist play a pivotal role throughout the continuum of care- from primary prevention and early detection to treatment support, rehabilitation and long-term surveillance. This review highlights the comprehensive role of dentistry in head and neck oncology.

Keywords: Head and Neck Cancer; Oral Oncology; Rehabilitation; Radiotherapy; Oral Cance

References

1. World Health Organization. “Cancer of the oral cavity and oropharynx”. Geneva: World Health Organization; (2020).
2. Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: A Cancer Journal for Clinicians6 (2018): 394-424.
3. Gupta B., et al. “Global epidemiology of head and neck cancers: a continuing challenge”. Oncology 1 (2016): 13-23.
4. Sonis ST. “Oral mucositis in cancer therapy”. Journal of Support Oncology 2 (2004): 3-8.
5. Epstein JB., et al. “Oral complications of cancer and cancer therapy”. CA: A Cancer Journal for Clinicians6 (2012): 400-422.
6. Peterson DE., et al. “Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines”. Annals of Oncology5 (2015): 139-151.
7. Neville BW and Day TA. “Oral cancer and precancerous lesions”. CA: A Cancer Journal for Clinicians4 (2002): 195-215.
8. Hong CHL., et al. “A systematic review of dental disease in patients undergoing cancer therapy”. Support Care Cancer 8 (2010): 1007-1021.
9. Lalla RV., et al. “MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy”. Cancer 10 (2014): 1453-1461.
10. Jensen SB and Peterson DE. “Oral complications of cancer therapy: current management and future directions”. Support Care Cancer7 (2014): 1917-1925.
11. Chabner BA., et al. “Chemotherapy and the war on cancer”. Nature Reviews Cancer 1 (2005): 65-72.
12. Longley DB and Johnston PG. “Molecular mechanisms of drug resistance”. Journal of Pathology 2 (2005): 275-292.
13. Epstein JB and Schubert MM. “Oral mucositis in myelosuppressive cancer therapy”. Oral Surgery, Oral Medicine, Oral Pathology 3 (1999): 273-279.
14. Elting LS., et al. “Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head and neck malignancies”. International Journal of Radiation Oncology, Biology, Physics4 (2007): 1110-1120.
15. Peterson DE. “Oral complications of chemotherapy”. Oral Surgery, Oral Medicine, Oral Pathology3 (1989): 272-279.
16. Sonis ST. Pathobiology of oral mucositis”. Oral Oncology4 (2004): 333-341.
17. Lalla RV., et al. “Management of oral mucositis in patients with cancer”. Dental Clinics of North America1 (2008): 61-77.
18. Crawford J., et al. “Chemotherapy-induced neutropenia”. Cancer2 (2004): 228-237.
19. Dale DC. “Neutropenia and neutrophilia”. Hematology, ASH Education Program (2002): 3-9.
20. Spielberger R., et al. “Palifermin for oral mucositis after intensive therapy for hematologic cancers”. The New England Journal of Medicine 25 (2004): 2590-2598.
21. Ferrara JL., et al. “Graft-versus-host disease”. Lancet 9674 (2009): 1550-1561.
22. Peterson DE., et al. “Cancer: Principles and Practice of Oncology”. 9^th Philadelphia: Lippincott Williams & Wilkins; (2011): 1205-1211.
23. Marx RE. “Osteoradionecrosis: a new concept of its pathophysiology”. Journal of Oral and Maxillofacial Surgery6 (1983): 351-357.
24. Regaud C. “Sur la nécrose des os atteints par un processus cancéreux”. Paris (1922).
25. Epstein JB., et al. “Osteoradionecrosis: clinical experience”. Oral Surgery, Oral Medicine, Oral Pathology 2 (1987): 197-203.
26. Beumer J., et al. “Osteoradionecrosis: predisposing factors and outcomes”. Oral Surgery, Oral Medicine, Oral Pathology4 (1984): 358-364.
27. Notani K., et al. “Management of osteoradionecrosis of the jaw”. Journal of Oral and Maxillofacial Surgery3 (2002): 268-275.
28. Nabil S., et al. “ncidence and prevention of osteoradionecrosis after dental extraction”. International Journal of Oral and Maxillofacial Surgery3 (2011): 229-243.
29. Chronopoulos A., et al. “Osteoradionecrosis of the jaw”. Journal of Craniomaxillofacial Surgery 2015;43 (2): 181-90.
30. Thorn JJ., et al. “Osteoradionecrosis of the jaws”. Radiotherapy Oncology2 (2000): 137-145.
31. Lyons A and Ghazali N. “Osteoradionecrosis of the jaws”. British Journal of Oral and Maxillofacial Surgery7 (2008): 523-528.
32. Marx RE and Johnson RP. “Studies in the radiobiology of osteoradionecrosis”. Oral Surgery, Oral Medicine, Oral Pathology4 (1987): 379-390.
33. Oh HK., et al. “Risk of osteoradionecrosis after extraction”. Journal of Oral and Maxillofacial Surgery 2004;62 (2): 139-44.
34. Reuther T., et al. “Osteoradionecrosis”. Journal of Oral and Maxillofacial Surgery8 (2003): 932-938.
35. Wahl MJ. “Osteoradionecrosis prevention myths”. Journal of the American Dental Association9 (2006): 1140-1149.
36. Delanian S and Lefaix JL. “The radiation-induced fibroatrophic process”. Radiotherapy Oncology2 (2004): 119-131.
37. Delanian S., et al. “Complete restoration of refractory mandibular osteoradionecrosis”. International Journal of Radiation Oncology, Biology, Physics3 (2011): 832-839.
38. Annane D., et al. “Hyperbaric oxygen therapy for radionecrosis”. Lancet 9438 (2004): 2011-2016.
39. Jensen SB., et al. “Salivary gland hypofunction and xerostomia in cancer patients”. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology6 (2010): 711-719.
40. Eisbruch A., et al. “Xerostomia and salivary gland sparing in head and neck radiotherapy”. International Journal of Radiation Oncology, Biology, Physics3 (2001): 695-704.
41. Dijkstra PU., et al. “Trismus in head and neck oncology: a systematic review”. Head and Neck6 (2004): 524-530.
42. Jager-Wittenaar H., et al. “Malnutrition in head and neck cancer patients”. Clinical Otolaryngology4 (2011): 330-336.
43. Marx RE. “Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws”. Journal of Oral and Maxillofacial Surgery9 (2003): 1115-1117.
44. Ruggiero SL., et al. “Medication-related osteonecrosis of the jaw—2014 update”. Journal of Oral and Maxillofacial Surgery10 (2014): 1938-1956.
45. Khan AA., et al. “Diagnosis and management of osteonecrosis of the jaw”. Journal of Bone Mineral Research1 (2015): 3-23.
46. Yarom N., et al. “Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline”. Journal of Clinical Oncology25 (2019): 2270-2290.
47. Otto S., et al. “Bisphosphonate-related osteonecrosis of the jaws: characteristics, risk factors, clinical features, localization and impact on oncological treatment”. Journal of Craniomaxillofacial Surgery1 (2012): 1-6.
48. Beth-Tasdogan NH., et al. “Interventions for managing medication-related osteonecrosis of the jaw”. Cochrane Database System Review 10 (2017): CD012432.
49. Beumer J., et al. “Maxillofacial rehabilitation: prosthodontic and surgical considerations”. 3^rd Carol Stream (IL): Ishiyaku EuroAmerica; (2011).
50. Granström G. “Radiotherapy, osseointegration and hyperbaric oxygen therapy”. Periodontology 2000 33 (2003): 145-62.
51. Epstein JB and Stevenson-Moore P. “Periodontal disease and head and neck cancer therapy”. Periodontology 2000 24 (2000): 47-57.
52. Scully C., et al. “Oral mucositis”. Oral Disease3 (2006): 229-241.
53. Worthington HV, ., et al. “Interventions for preventing oral mucositis for patients with cancer receiving treatment”. Cochrane Database System Review 4 (2007): CD000978.
54. Vissink A., et al. “Oral sequelae of head and neck radiotherapy”. Critical Reviews in Oral Biology and Medicine 3 (2003): 199-212.
55. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia”. Head and Neck1 (2007): 58-63.
56. Gambichler T., et al. “Imatinib mesylate-associated hyperpigmentation of skin and mucosa”. Journal of the American Academy of Dermatology5 (2005): 895-896.
57. Eisen D and Hakim MD. “Oral mucosal pigmentation associated with imatinib mesylate therapy”. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology2 (2004): 176-179.
58. Arora A., et al. “Gingival and dental pigmentation induced by imatinib mesylate: a case report”. Journal of Oral and Maxillofacial Pathology2 (2012): 282-285.
59. Yong CW., et al. “Dental evaluation prior to cancer therapy”. Frontiers in Oral Health 3 (2022): 876941.
60. Owosho AA., et al. “The role of dental practitioners in the management of oncology patients: the head and neck radiation oncology patient and the medical oncology patient”. Dental Journal (Basel) 11 (2023): 136.
61. Barclay Stewart C and Turani D. “Current practice in dental oncology in the UK”. Dental Update 8 (2010): 555-561.

Citation

Citation: Abhishek Kumar Pandey., et al. “Dentistry in Head and Neck Oncology: From Prevention to Rehabilitation – A Review". Acta Scientific Dental Sciences 10.9 (2026): 28-38.

Copyright

Copyright: © 2026 Abhishek Kumar Pandey., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.